The use of intra-detrusor onabotulinumtoxinA in patients with myasthenia gravis

Abstract

The use of intra-detrusor onabotulinumtoxinA (Botox®) in patients with myasthenia gravis has not been reported, and little evidence exists to substantiate a complete contraindication of Botox use in this population. Here, we present two cases of comorbid overactive bladder (OAB) and myasthenia gravis successfully treated with intra-detrusor Botox.